Stay updated with breaking news from Sarepta Elevidys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With several recent approvals in the space and more on the horizon, BioSpace looks at some of the key decisions and their larger significance both for patients and science.
The threat is still emerging, but it could be significant.
Novo Nordisk recently acquired three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
Sarepta Therapeutics’ Elevidys failed to meet its primary endpoint in a Phase 3 trial, shortly after the FDA granted it accelerated approval for Duchenne muscular dystrophy.
June 23 (Reuters) - Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approva...